Jersey City, NJ
Director, Patient Reported Outcomes, GlaxoSmithKline
Represented: Industry (Pharmaceutical)
Steven I. Blum is Director, Patient Reported Outcomes in the Value Evidence and Outcomes Division at GlaxoSmithKline, where he provides strategic and technical support for patient focused outcomes. He has over 20 years of commercial and scientific experience in the pharmaceutical industry and, in 2011, was selected by Pharmaceutical Executive as one of its Emerging Pharma Leaders, an annual recognition of rising industry executives. He serves as co-Chair for the Critical Path Institute’s Patient-Reported Outcome Consortium Communications subcommittee and co-Chair of the PROMIS Industry Interest Committee, and is a member of the International Society of Quality of Life Research, the Society For Pharmacoeconomics and Outcomes Research, and other professional societies. He received a BBA from University of Massachusetts at Amherst, a MBA from Fordham University, and a MA in Economics from The New School for Social Research.
Blum served as a member of the Advisory Panel on Patient Engagement from April 2014 - April 2017.
Conflict of Interest Disclosures
As of November 15, 2016:
- Stock Owned: GlaxoSmithKline, Forest Research Institute, Inc.
- GlaxoSmithKline, Director, Patient Reported Outcomes
- Forest Research Institute, Director, Health Economics (prior employment in the last 12 months)